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The cytochrome P450 (CYP450) enzymes and ABC drug transporters in the intestine and liver play a major role in the pharmacokinetics of drugs and other
xenobiotics. If feed and food components also affect these enzymes or transporters, then the disposition of drugs can be altered leading to clinically relevant
interactions. However, little is known about pharmacokinetic interactions between drugs and food or feed contaminants. Mycotoxins are such contaminants
produced by fungi and are the number one threat regarding chronic toxicity. Moreover, our research group has shown a reduction in hepatic CYP3A activity in
pigs (Goossens et al., 2013), and a down-regulation of hepatic CYP3A37, CYP1A4, CYP1A5 and MRP2 in broiler chickens after exposure to T-2 toxin (Osselaere
et al., 2013). Therefore it is the aim of this project to investigate the influence of oral exposure to Fusarium mycotoxins on the pharmacokinetic behavior of
drugs which are substrates for these enzymes and transporters.
In vitro experiments:
Different experiments will be set-up (fig 1), The first step is to characterize key
hepatic/intestinal metabolizing enzymes and transporters and incubate them
with different Fusarium mycotoxins. For transporters, fresh tissue as wel as
cell cultures will be used to asses their activity and the effect of mycotoxins on
the activity. Also the gene expression will be assesed using qPCR.
Feed trial:
Next, a trial with contaminated feed will be
carried out and tissue collected to perform the
same in vitro experiments as before
Figure 1: Flow of the in vitro experiments. From left to right:
microsomal incubation with mycotoxins, qPCR, cell line
transport experiments and transporter activity determination
with Ussing chambers.
In vivo experiments:
Mycotoxins with significant effect on CYP450
enzymes/drug transporters will be used to conduct
an in vivo trial with relevant substrate drugs to
determine changes in pharmacokinetic behavior
The validated method is suited for analysis of the microsomal incubation mixtures. Hence, the inhibitory
potential of several mycotoxins on CYP450 enzymes can be assessed. Together with the results from
the qPCR method (under development), this will give reveal the effect of mycotoxins on drug
metabolizing enzymes.
Probe 1 Probe 2 Probe 3 Probe 4 Probe 5
range (ng/ml) 2-1000 10-1000 2-1000 1-1000 2-1000
Acquisition mode ESI+ ESI+ ESI+ ESI- ESI-
Accuracy (%) QC-low -5.0 7.8 6.3 -5.0 2.5
QC-mid -0.2 -1.4 3.4 -0.9 -6.9
QC-high 3.0 6.5 2.7 4.1 -1.1
Precision 
within day (%)
QC-low 6.7 0.7 25.0 5.8 14.1
QC-mid 3.2 5.2 6.5 2.3 4.9




QC-low 10.4 7.2 21.9 12.0 9.4
QC-mid 3.1 7.2 6.5 5.0 7.8
QC-high 4.9 4.4 14.8 5.8 8.5
LOQ (ppb) 2.00 10.0 2.00 1.00 2.00
LOD (ppb) 0.22 0.59 0.03 0.01 0.12
Gof (%) 2.37 4.63 10.76 7.45 4.22
Development and validation of a multiprobe HPLC-MS/MS method to assess CYP450 activity.
Validation results are displayed in table 1.
Table 1: Validation results for the LOQ, limit of quantification; LOD, limit of
detection; Gof, goodness of fit; accuracy and precision; QC, quality control
sample
Sample preparation:
•50 µL porcine hepatic microsomes (1.25mg protein/ml); 50 µL probe solution (probe 1-5); 50µL 
buffer (pH 7.4); 50µL NADPH (5mM); 50µL KCl (1.15%) and 25 µL stop reagent containing the 
internal standards.
•Samples with different probes are pooled
•Extraction with 5mL ethyl acetate, evaporation to dryness (N2, 40°C)
•Reconstitution in water/methanol 50/50 (v/v)
Chromatography:
•HPLC instrument: Alliance type 2695 HPLC (Waters) 
•HPLC-column: Zorbax Eclipse Plus column (C18, 3.0 x 100 mm, d.p.: 3.5 µm) in combination 
with a guard column (2.1 x 12.5 mm, d.p.: 5 µm), both from Agilent Technologies (Sint-
Katelijne-Waver, Belgium)
•Mobile Phase: (A) 0.1% formic acid in water; (B) 0.1% formic acid in acetonitrile, gradient 
elution
MS/MS detection:
•MS instrument: Quattro Ultima® triple quadripole MS (Micromass)
•MS conditions: ESI+ (probe 1-3); ESI- (probe 4, 5)
•MRM transitions are depicted in figure 2
Figure 2: MRM* transitions for the different probes. First two rows ESI-, last
three rows ESI+. * only one of two transitions depicted for each probe.
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